These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 15885230)

  • 1. The value of biliary amylase and Hepatocarcinoma-Intestine-Pancreas/Pancreatitis-associated Protein I (HIP/PAP-I) in diagnosing biliary malignancies.
    Chen CY; Lin XZ; Wu HC; Shiesh SC
    Clin Biochem; 2005 Jun; 38(6):520-5. PubMed ID: 15885230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of biliary fibronectin for diagnosis of cholangiocarcinoma.
    Chen CY; Lin XZ; Tsao HC; Shiesh SC
    Hepatogastroenterology; 2003; 50(52):924-7. PubMed ID: 12845951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology.
    Rosty C; Christa L; Kuzdzal S; Baldwin WM; Zahurak ML; Carnot F; Chan DW; Canto M; Lillemoe KD; Cameron JL; Yeo CJ; Hruban RH; Goggins M
    Cancer Res; 2002 Mar; 62(6):1868-75. PubMed ID: 11912167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trypsinogen activation peptide (TAP) expression in gallbladder bile identifies bilio-pancreatic carcinoma.
    Brockmann JG; Hernandez CA; Emparan C; Wolters H; Haier J; Dietl KH; Senninger NJ
    Anticancer Res; 2003; 23(2A):819-25. PubMed ID: 12820306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocarcinoma-intestine-pancreas/pancreatic associated protein (HIP/PAP) is expressed and secreted by proliferating ductules as well as by hepatocarcinoma and cholangiocarcinoma cells.
    Christa L; Simon MT; Brezault-Bonnet C; Bonte E; Carnot F; Zylberberg H; Franco D; Capron F; Roskams T; Bréchot C
    Am J Pathol; 1999 Nov; 155(5):1525-33. PubMed ID: 10550309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic role of biliary pancreatic elastase for cholangiocarcinoma in patients with cholestasis.
    Chen CY; Tsai WL; Wu HC; Syu MJ; Wu CC; Shiesh SC
    Clin Chim Acta; 2008 Apr; 390(1-2):82-9. PubMed ID: 18252202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice.
    Ohshio G; Manabe T; Watanabe Y; Endo K; Kudo H; Suzuki T; Tobe T
    Am J Gastroenterol; 1990 Oct; 85(10):1370-6. PubMed ID: 2220731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.
    Kim HJ; Kim MH; Myung SJ; Lim BC; Park ET; Yoo KS; Seo DW; Lee SK; Min YI
    Am J Gastroenterol; 1999 Jul; 94(7):1941-6. PubMed ID: 10406263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical value of pancreatitis-associated protein in acute pancreatitis.
    Pezzilli R; Billi P; Migliori M; Gullo L
    Am J Gastroenterol; 1997 Oct; 92(10):1887-90. PubMed ID: 9382059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical treatment for non-dilated biliary tract with pancreaticobiliary maljunction should include excision of the extrahepatic bile duct.
    Hara H; Morita S; Ishibashi T; Sako S; Dohi T; Iwamoto M; Tanigawa N
    Hepatogastroenterology; 2001; 48(40):984-7. PubMed ID: 11490854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated urinary levels and urothelial expression of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein in patients with interstitial cystitis.
    Makino T; Kawashima H; Konishi H; Nakatani T; Kiyama H
    Urology; 2010 Apr; 75(4):933-7. PubMed ID: 19646740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibronectin in human bile fluid for diagnosis of malignant biliary diseases.
    Körner T; Kropf J; Hackler R; Brenzel A; Gressner AM
    Hepatology; 1996 Mar; 23(3):423-8. PubMed ID: 8617420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The assessment of biliary CA 125, CA 19-9 and CEA in diagnosing cholangiocarcinoma--the influence of sampling time and hepatolithiasis.
    Chen CY; Shiesh SC; Tsao HC; Lin XZ
    Hepatogastroenterology; 2002; 49(45):616-20. PubMed ID: 12063953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatitis-associated protein (PAP) in patients with pancreatic cancer.
    Cerwenka H; Aigner R; Bacher H; Werkgartner G; el-Shabrawi A; Quehenberger F; Mischinger HJ
    Anticancer Res; 2001; 21(2B):1471-4. PubMed ID: 11396234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gallbladder bile tumor marker quantification for detection of pancreato-biliary malignancies.
    Brockmann J; Emparan C; Hernandez CA; Sulkowski U; Dietl KH; Menzel J; Wolters H; Glodny B; Senninger N
    Anticancer Res; 2000; 20(6D):4941-7. PubMed ID: 11326643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
    Ozkan H; Kaya M; Cengiz A
    Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Technetium-99m-pyridoxylideneglutamate: a new hepatobiliary radiopharmaceutical. II. Clinical aspects.
    Ronai PM; Baker RJ; Bellen JC; Collins PJ; Anderson PJ; Lander H
    J Nucl Med; 1975 Aug; 16(8):728-37. PubMed ID: 1177049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Occult pancreaticobiliary reflux in gallbladder cancer and benign gallbladder diseases.
    Beltrán MA; Vracko J; Cumsille MA; Cruces KS; Almonacid J; Danilova T
    J Surg Oncol; 2007 Jul; 96(1):26-31. PubMed ID: 17345616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Fibronectin in human bile--a new parameter for diagnosis of malignant bile duct processes?--A pilot study].
    Körner T; Kropf J; Jaspersen D; Schorr W; Hammar CH; Gressner AM
    Z Gastroenterol; 1994 Feb; 32(2):87-90. PubMed ID: 8165831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can red cell distribution width help to discriminate benign from malignant biliary obstruction? A retrospective single center analysis.
    Beyazit Y; Kekilli M; Ibis M; Kurt M; Sayilir A; Onal IK; Purnak T; Oztas E; Tas A; Yesil Y; Arhan M
    Hepatogastroenterology; 2012; 59(117):1469-73. PubMed ID: 22683963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.